From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Combination of
RifampicinRifamycin antibiotic
IsoniazidAnti-tuberculosis medication
PyrazinamideAnti-tuberculosis medication
Clinical data
Trade namesRifater, Trifazid, others
AHFS/Drugs.comFDA Professional Drug Information
License data
  • C
Routes of
by mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
CAS Number
  • 161935-14-4
PubChem CID
  • none

Rifampicin/isoniazid/pyrazinamide, also known as rifampin/isoniazid/pyrazinamide, and sold under the trade name Rifater, is a medication used to treat tuberculosis.[1] It is a fixed dose combination of rifampicin, isoniazid, and pyrazinamide.[1] It is used either by itself or along with other antituberculosis medication.[1] It is taken by mouth.[1]

Side effects are those of the underlying medications.[1] These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness.[2] Severe side effects include liver problems.[3] Use in those under the age of 15 may not be appropriate.[3] It is unclear if use in pregnancy is safe for the baby.[3]

Rifampicin/isoniazid/pyrazinamide was approved for medical use in the United States in 1994.[3] It is on the World Health Organization's List of Essential Medicines.[4]

Medical uses[edit]

The hope of a fixed-dose combination pill is to increase the likelihood that people will take all of three medications.[5] Also, if people forget to take one or two of their drugs, they might not then develop resistance to the remaining drugs.

Society and culture[edit]

It is manufactured by Aventis.[citation needed]

See also[edit]


  1. ^ a b c d e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 143. hdl:10665/44053. ISBN 9789241547659.
  2. ^ "Rifater Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
  3. ^ a b c d "Rifater - FDA prescribing information, side effects and uses". www.drugs.com. October 2016. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
  4. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. ^ Brown, Morris J.; Sharma, Pankaj; Bennett, Peter N. (30 July 2012). Clinical Pharmacology. Elsevier Health Sciences. p. 204. ISBN 978-0-7020-5113-5.